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of new or recurrent VTE and major bleeding were compa-
rable to the cancer subgroup analysis from the EINSTEIN 
studies. The results of our Clinical Pathway provide guid-
ance on Rivaroxaban use for treatment of CAT, and suggest 
that safety and efficacy is preserved, compared with past-
published experience with LMWH.
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Introduction
Cancer and its treatment are commonly complicated by 
venous thromboembolic (VTE) episodes, which remain 
a leading cause of morbidity and mortality in the cancer 
patient [1–3]. Management of cancer-associated throm-
bosis (CAT) remains problematic. Two randomized trials 
showed superior efficacy of low-molecular weight heparin 
(LMWH) to vitamin K antagonist (VKA) for management 
of cancer-associated thrombosis (CAT), [4, 5] us estab-
lishing LMWH therapy as the standard of care [6]. How-
ever, LMWH therapy requires uncomfortable injections on 
a daily or twice daily basis, as well as substantial cost, even 
for currently ava lable generic forms [7].
Recently, several new direct oral anticoagulants 
(DOAC’s) have become available for the treatment of VTE, 
as well as for other anticoagulation indications [8–12]. 
Riva oxaban is a direct inhibitor of activated coagulation 
factor X and received approval in 2012 for treatment of 
VTE, following the EINSTEIN-PE and EINSTEIN-DVT 
trials [8–12]. The EINSTEIN trials compared rivaroxaban 
wi h a VKA in a general medical population, demonstrat-
ing non-inferiority of efficacy and significant reduction in 
major bleeding [8–12]. However, the EINSTEIN trials do 
Abstract Low-molecular weight heparin (LMWH) has 
been the standard of care for tr atment of venous thrombo-
embolism (VTE) in patients wi h cancer. Rivaroxaban was
approved in 2012 for the treatment of pulmonary embolism
(PE) and deep vein thrombosis (DVT), but no pri r stud-
ies have been reported specifically evaluating the efficacy 
and safety of rivaroxaban for cancer-associated thrombosis 
(CAT). Under a Quality Assessment Initiative (QAI), we 
established a Clinical Pathway to guide rivaroxaban use 
for CAT and now report a validation analysis of our first 
200 patients. A 200 patient cohort with CAT (PE or symp-
tomatic, proximal DVT), whose full course of anticoagu-
lation was with rivaroxaban, were accrued. In competing 
risk analysis, primary endpoints t 6 months included new 
or recurrent PE or symptomatic proximal l wer extremity 
DVT, major bleeding, clinically-relevant non-major bleed-
ing leading to discontinuation of rivaroxaban, or death. 
In competing risk analysis, the 6 months cumulative inc-
dence of new or recurrent VTE was 4.4 % (95 % CI = 1.4–
7.4 %), major bleeding was 2.2 % (95 % CI = 0−4.2 %) and 
all-cause mortality 17.6 % (95 % CI = 11.7–23.0 %). In this 
cohort of 200 patients with active cancer and CAT the rates 
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contraindications to the use of rivaroxaban. A platelet count 
of 50,000/mcL or less, but ≥25,000/mcL led to a dose 
reduction, while the drug was held for a platelet count below 
25,000/mcL. Some patients were treated with rivaroxaban 
despite relative contraindications. All patients who received 
rivaroxaban for CAT were included in the cohort analysis, 
regardless of compliance with the Clinical Pathway.
Patients and outcomes
This project was conducted as an MSK Quality Assessment 
Initiative. The pre-specified goal was to track an initial cohort 
of 200 patients with cancer-associated pulmonary embolism 
(PE) or symptomatic proximal deep vein thrombosis (DVT), 
with a plan for at least 6 months of rivaroxaban treatment. 
Within this initiative, all patients who have had a rivaroxa-
ban order on or after January 1, 2014 are entered in the data-
base. The electronic medical record (EMR) is examined on 
all patients for cancer type, stage, initial thrombosis or other 
anticoagulation indication, and rivaroxaban dose and timing. 
We identified the initial 200 patients who had sustained an 
acute cancer-associated PE or symptomatic, proximal DVT 
and had been started on rivaroxaban for this indication. A 
VTE was deemed cancer-associated if the patient had active 
cancer, was receiving cancer-directed medical or radiation 
therapy, or the thrombotic episode had occurred within 30 
days of cancer-related surgery. We included patients who had 
received up to 3 days of a parenteral anticoagulant as initial 
treatment prior to change to rivaroxaban. Patients with local-
ized squamous cell carcinoma or basal cell carcinoma of 
the skin were not included in this cohort analysis. All study 
patients were followed at MSK after their initial diagnosis of 
CAT, even though they have received some of their cancer 
treatment locally as well. Patients who left MSK before the 
end of the 6-month mandatory observation period were cen-
sored as of the time of their last visit with us, or last available 
medical record from outside provider.
All clinical notes were reviewed by a combination of 
automated text search and review by an investigator, to 
detect bleeding or thrombotic episodes. The list of keywords 
is provided in Appendix 2. All clinical notes containing any 
keyword were first identified by an automated text search 
then reviewed by a physician (SM, GAS or EL). Outside 
medical records were read manually. Endpoints of interest 
included recurrent VTE (definition derived from the one 
used in the CLOT trial [4]), major bleeding (as defined by the 
International Society on Thrombosis and Haemostasis [13]), 
clinically-relevant non-major bleeding (CRNMB) leading to 
discontinuation of rivaroxaban, and death from any cause.
The R statistical software platform was used along with 
the TM package to process the clinical notes. All-cause 
mortality was also assessed based on the EMR. The date of 
transfer to hospice for terminal care was entered as the date 
not provide sufficient guidance for use of rivaroxaban in 
CAT. The control arm in EINSTEIN was a VKA, n  longer
considered standard of care for CAT. Second y, only about 
5 % of the patients in EINSTEIN had a tive cancer, and the 
nature and severity of those canc r subgroups may not be 
truly representative of the broader c cer population. Lastly, 
the EINSTEIN trials did not address the specific situations 
that arise during the course of cancer therapy such as tran-
sient thrombocytopenia, possible absorption and excretion 
defects, and interruptions for invasive procedures.
It is premature to extrapolate the EINSTEIN results to the 
general cancer population. This leav s a “knowledge gap,” 
where rivaroxaban is approved for treatmen  of VTE, but 
there has not been sufficient guidance on safe and effective 
use in the CAT specific population. To address this knowl-
edge gap, the Hematology/Anticoagulation Management 
Service at Memorial Sloan Kettering Cancer Center, in con-
sultation with expert pharmacists and published literature, 
derived a Clinical Pathway for rivaroxaban at th  end of
2013. The Clinical Pathway addresses issues specific to the 
cancer population, including potent al b orptio  defects, 
excretory organ function, drug interactions, thrombocyto-
penia, and bleeding risk. We ow report on n initial 200 
patient cohort with CAT, managed with th  Clinical Path-




The Clinical Pathway (Appendix 1) was devised b the 
authors (SM, SH, and GAS) and se ved as a guide for tr at-
ment of venous thromboembolic events (VTE) with riva-
roxaban within Memorial Sloan Kettering (MSK). The 
Pathway largely reflected the FDA approved medication 
guide, but also accounted for anticipated situations arising 
within the course of cancer care. Th  usual sta ting dose was 
15  mg orally twice daily for 3 w eks followed by 20 mg 
daily. For cancer patients aged 75 years or older the dose 
was reduced to 10 mg twice daily for 3 weeks followed by 
15  mg daily based on an anticipated decr ase in drug clear-
ance for this demographic group.
Several relative contra-i dications were stablished as 
part of the Clinical Pathway. Cr at in  clea ance <30 mL/
min, liver function tests greater ha  three times the upper 
limit of normal, expected ma absorption at the level of the 
stomach or small bowel, active genitourinary (GU) or gas-
trointestinal (GI) lesions, untr ated primary central n rvous 
system neoplasm, a body weig t<50 or >150  kg, the use 
of any antiplatelet agent other than pirin 81 mg daily 
and any significant drug interaction all constituted relative 
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sudden death or major bleeding. The records recorded deaths 
as “cancer-related” in 19 cases and “unknown” in all other 
instances. Other notable events, not included as primary end-
points, included four instances of tumor associated visceral 
vein thrombosis, one left hepatic vein thrombosis, and one 
ischemic stroke in patients on rivaroxaban. Eight patients 
had their dose of rivaroxaban decreased following the occur-
rence of an episode of CRNMB. Of these, there was one fur-
ther major bleed and one CRNMB leading to discontinuation 
of rivaroxaban on the reduced dose. The 6-month cumulative 
incidence estimates for competing endpoints were; recurrent 
VTE, 4.4 % (95 % CI = 1.4–7.4 %); major bleeding, 2.2 % 
(95 % CI = 0−4.2 %); CRNMB leading to discontinuation of 
rivaroxaban, 3.8 % (95 % CI = 1.0−6.5 %); all-cause mortal-
ity, 17.6 % (95 % CI = 11.7–23.0 %). The plots for the cumu-
lative incidence functions are shown in Fig. 1.
We performed a subgroup analysis of the 39 patients aged 
75 years or older. The 6-month cumulative incidence values 
for recurrent VTE, major bleeding, and CRNMB leading 
to discontinuation were 5.3 % (95 % CI = 0−12.1 %), 2.6 % 
(95 % CI = 0−7.4 %) and 3.0 % (95 % CI = 0−8.7 %) respec-
tively. These results were comparable to those of patients 
under the age of 75 years.
A total of 27 patients went off rivaroxaban prior to 
reaching a primary endpoint or 6 months of planned 
of death due to difficulties assessing outcomes after such a 
change in plan of care.
The endpoint assessment on the 200-patient cohort was 
conducted when the final patient reached an endpoint or had 
been observed for at least 6 months.
Statistical analysis
We initially conducted univariate analysis in order to assess 
the characteristics of cohort members along with time-to-
event information based on the cumulative incidence for 
competing risks. Recurrent VTE, major bleeding, CRNMB 
leading to discontinuation of rivaroxaban and death from 
any cause were considered competing risks for the purpose 
of the analysis. The R 3.2.3 for Windows software platform 
was used, along with the Survival package.
Results
Recruitment started on January 1, 2014. The first and last 
individuals to enter the cohort did so on January 25, 2014 
and May 19, 2015 respectively. Patient characteristics are 
shown in Table 1, inc uding the distribution of cancer types. 
The core cohort consisted of 200 patients, of whom 136 had 
sustained a PE (with or without DVT) and 64 had experi-
enced a symptomatic, proximal lower extremity DVT as the 
index event. 183 patients had a solid tumor and 17 patients 
had a hematological malignancy. Stage was advanced for 
most cohort members, with 23 cases of stage III and 142 
cases of metastatic disease for solid tumors (exc uding brain 
primary). The mean age was 63 years, w th 40 % of pati nt  
being male.
Primary endpoints
As of November 17, 2015 all patients in the cohort either had 
sustained an endpoint, had been observed at least 6 months on 
anticoagulation, or were censored as of he ime f their last 
visit at MSK if they transferred their cancer care to another 
institution. No patient was lost to followup. At the 6 months 
time-point, the EMR was queried for cli ical notes and the 
algorithm described above was applied in order to detect per-
tinent thrombotic and bleeding episodes. In the first 6 months 
of treatment, there were eight cases of recurrent VTE, four 
cases of major bleeding, seven ca es of CRNMB leading to 
discontinuation of rivaroxaban and 31 deaths.
We reviewed the last notes and death notification for 
all 31 deceased individuals. In 24 cases, patients had been 
transferred to hospice, at which point rivaroxaban is usu-
ally discontinued and scant data exists about the cause of 
death. For the seven individuals who did not die under hos-
pice care, a review of the record did not reveal a y notion of 






PE, with or without DVT 136
Proximal, symptomat c lower extremity DVT64
















PE pulmonary embolism, DVT deep vein thrombosis
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for 24 h. Rivaroxaban was not held in four cases: one was 
a diagnostic endoscopy, and three were emergency proce-
dures. Documentation of rivaroxaban management was 
unclear in one additional case.
No major bleeding episode occurred during the interrup-
tion of rivaroxaban, within 7 days of the procedure. Only 
one patient developed a recurrent VTE following interrup-
tion for a procedure. That patient was a 52-year-old woman 
with stage IV ovarian cancer who had multiple discontinu-
ations of rivaroxaban for debulking surgery and subsequent 
abscess drainages. Three days after an abscess drainage, 
prior to restarting rivaroxaban, she developed a symptom-
atic popliteal vein DVT. Of note, this patient was heterozy-
gous for both factor V Leiden and prothrombin G20210A, 
with a history of multiple thromboses prior to her cancer, 
and therefore was at particularly high risk for VTE.
Thrombocytopenia
There were 11 episodes of thrombocytopenia (platelets 
<50,000/mcL) in ten patients (Table 2). Rivarox an was 
held in seven episodes, and dose-reduced in one episode. 
In three episodes rivaroxaban dose was not adjusted, two 
of those cases only a single platelet count below 50,000/
mcL and one patient had already been on reduced dose of 
rivaroxaban. There was no MB, CRNMB leading to drug 
discontinuation, death or recurrent VTE associated with an 
episode of thrombocytopenia.
Renal insufficiency
Transient renal insufficiency, as defined by a creatinine 
clearance of <30 mL/min (using Cockroft–Gault equation 
[14]) was observed in seven episodes in five patients during 
rivaroxaban treatment (Table 2). Rivaroxab n dose was held 
in two episodes, and not altered in five episodes. None of the 
patients experienced a major bleed, CRNMB, or recurrent 
VTE event within 7 days of such an episode.
anticoagulation. The drug was st pped due to an upcom-
ing surgical procedure in eight cases (and no rest rt d), for 
a medical reason in 18 cases, and following the patient’s 
wishes in one case. Slightly more than half of p ients (105 
individuals) were observed for th full 6 months, with an 
observation time range of 4–182 days for the whole cohort.
Additional events
Invasive procedures
There were 70 invasive procedure  during th  rivaroxaban 
treatment period (Table 2). In 59 procedures rivaroxaban 
was held for at least 48 h, nd in six procedures it was hel  
Table 2 Management of rivaroxaban anticoagulation in the setting of thrombocytopenia, renal insufficiency, liver dysfunction and invasive pro-
cedures















Platelet count <50,000/mcL (N = 11) 1 7 3 0 0 0 0
Creatinine clearance <30 mL/min (N = 7) 0 2 5 0 0 0 1
Elevated liver enzymes (AST, ALT or bilirubin  
>3 × upper limit of normal) (N = 18)
0 6 12 0 1 0 1
Interventionsb (N = 70) 0 65 4 0 0 1 3
aCRNMB leading to discontinuation of Rivaroxaban
bThe exact management approach is unknown in the case of one intervention
Fig. 1 Cumulative incidence for competing risks
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This cohort study also provides some guidance regarding 
the anticipated confounding situations that frequently arise 
in the cancer setting, including interruption for procedure, 
thrombocytopenia, and transient organ dysfunction. Further, 
our empirical decision to dose-reduce in the elderly was 
associated with comparable bleeding rates with the over-
all population and was not associated with a trend towards 
significant loss of efficacy. Further support for the Clinical 
Pathway will require expansion of the number of patients 
treated under these guidelines.
The non-randomized nature of our cohort, which allowed 
patients and caregivers to choose between rivaroxaban and 
enoxaparin, could in theory result in selection bias. How-
ever this would be unlikely given the small numbers of indi-
viduals who were treated with a LMWH at our institution 
during the period of this cohort study. The primary reason 
patients were not treated with rivaroxaban was the presence 
of an active GU or GI tract lesion, which we estimated was 
<5  % of patients with a new cancer-associated thrombosis, 
so we do not believe this issue is of material importance for 
external validity.
This QAI was undertaken to provide guidance on the 
safety and efficacy of treatment of cancer-associated VTE 
with rivaroxaban. As we acknowledged, there has been a 
knowledge gap in this niche, where rivaroxaban has been 
approved for use, but there have been no prospective ran-
domized studies directly comparing rivaroxaban to LMWH. 
As such, our objective was to develop and prospectively 
validate a Clinical Pathway for this situation, providing 
guidance and reassurance to the providers and patients who 
have been faced with the burdensome alternative of the cost 
and inconvenience of LMWH.
Given the small sample size and non-randomized nature 
of this study, further investigation will be required to estab-
lish the safety, efficacy and comparability to a LMWH, the 
current standard of care. However, there are hurdles before 
such a clinical trial might be successfully performed. One 
major issue would be reluctance of patients to participate, 
given that the oral agent has already been approved for the 
treatment of VTE in the general population. Until the results 
of such a direct comparison become available, our data pro-
vide reassurance for the use of rivaroxaban in the setting of 
CAT.
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Elevated liver enzymes
There were 18 episodes of eleva ed liver enzymes (aspar-
tate transaminase, alanine transamin e or bilirubin >3 
times the upper limit of normal) in 14 p tients (Table 2). 
Rivaroxaban dose was held through six episodes nd not 
modified in 12 episodes. One patient experienced CRNMB, 
which led to discontinuatio  of rivaroxaban. No patient 
experienced a MB or recurrent VTE event within 7 days of 
such an episode.
Discussion
This is the first reported prospective cohort study of rivar-
oxaban therapy, specifically targeting CAT. In this cohort of 
200 patients with active cancer and a new VTE episode, riva-
roxaban use was found to be safe and effective when using a 
Clinical Pathway which accounts for situations specific to the 
oncology setting. Acknowledging differenc s n me odology,
the risk of recurrent VTE and major b eeding in our cohort with 
rivaroxaban compared well with results from p ior randomized 
trials using a LMWH for treatment o  ancer-associa ed VTE. 
In two published trials of dal eparin, at 6 months the risk of 
recurrent VTE was 8.7 and 9 % and the risk of major bleeding 
was 6 and 10.2 % [4, 5]. In regards to this ior evidence base, 
78  % of patients with a solid tumor in our cohort had metastatic 
disease versus 67 % for the CLOT study [4]. This sugge ts that 
patients in our group had a sim l r if not worst cancer comor-
bidity status compared to that of the CLOT trial.
Two recent papers have report d ca cer subgroup analy-
sis of rivaroxaban and apix ban for treatment of VTE. Prins 
and colleagues reported cancer subgroup analysis of the 
EINSTEIN studies of rivaroxaban for treatment of VTE, 
indicating similar rates of r current VTE (5 %) and major 
bleeding (2 %) to our new findings [16]. And more recently, 
Agnelli and colleagues performed a ca cer subgroup anal-
ysis of treatment of VTE with apixaban in the AMPLIFY 
study, also showing comparable ra es of recurrent VTE and 
major bleeding [17]. But both of those studies encompassed 
general medical populations with VTE, and the cancer su-
groups were not the primary focus, nd likely did not r pre-
sent the full spectrum of cancer stages.
Our Clinical Pathway and cohort study of rivaroxaban 
for CAT only allow for indire t compar on with the past 
CLOT and DALTECAN studies of LMWH. But there does 
not appear to be evidence of loss of safety or efficacy by use 
of rivaroxaban for treatment of cancer ss ci ted VTE. And 
our all-cause mortality at 6 months of 17.6 % was lower 
than in the LMWH studies [4, 15]. We do not claim fro  o r 
study that rivaroxaban is associated with superior mortality, 
compared with LMWH, but at least there is o evidence of 
an inferior cancer outcome.
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